Mediwound Ltd Ord Sh (MDWD)

$17.60 +0.22 (1.24%)
Market Cap 190.28M
Revenue (ttm) 20.22M
Net Income (ttm) -30.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -149.46%
Debt to Equity Ratio 0.04
Volume 79,400
Avg Vol 64,256
Day's Range N/A - N/A
Shares Out 10.81M
Stochastic %K 25%
Beta 0.21
Analysts Strong Sell
Price Target $30.67

Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and ot...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 797 14100
Fax: 972 7 797 14111
Address:
42 Hayarkon Street, Yavne, Israel
novelty
novelty Aug. 22 at 3:56 PM
$MDWD Bidless warrior
0 · Reply
novelty
novelty Aug. 22 at 1:59 PM
$MDWD bahahaha hah
0 · Reply
novelty
novelty Aug. 22 at 1:41 PM
$MDWD the Bidless warrior
0 · Reply
novelty
novelty Aug. 22 at 1:34 PM
$MDWD lmfao
0 · Reply
novelty
novelty Aug. 21 at 1:59 PM
$MDWD lmfao tank it market maker
0 · Reply
novelty
novelty Aug. 21 at 1:44 PM
$MDWD worst company ever the way this trades someone should be charged with manipulation
0 · Reply
novelty
novelty Aug. 21 at 1:40 PM
$MDWD should be able to scoop 14’s again now that Zee Contrarian is pumping.
0 · Reply
novelty
novelty Aug. 20 at 8:36 PM
$MDWD zee contrarian is a pumper
0 · Reply
JohnPDaly
JohnPDaly Aug. 20 at 6:32 PM
$MDWD https://x.com/zeecontrarian1/status/1958232584170746315?s=12
1 · Reply
novelty
novelty Aug. 20 at 3:30 PM
$MDWD the trading here is so controlled it’s hilarious.
0 · Reply
Latest News on MDWD
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 7:30 AM EDT - 3 days ago

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 1:31 PM EDT - 9 days ago

MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript

MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 7:00 AM EDT - 9 days ago

MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

Aug 13, 2025, 8:45 AM EDT - 10 days ago

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

MediWound to Report Second Quarter 2025 Financial Results

Aug 4, 2025, 7:30 AM EDT - 19 days ago

MediWound to Report Second Quarter 2025 Financial Results

MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025, 12:46 PM EDT - 3 months ago

MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 21, 2025, 7:00 AM EDT - 3 months ago

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

MediWound Ltd.: Undervalued High-Growth Potential

May 16, 2025, 10:34 AM EDT - 3 months ago

MediWound Ltd.: Undervalued High-Growth Potential

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

May 13, 2025, 7:30 AM EDT - 3 months ago

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

MediWound to Report First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 3 months ago

MediWound to Report First Quarter 2025 Financial Results

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

Apr 28, 2025, 8:00 AM EDT - 4 months ago

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 12:10 PM EDT - 5 months ago

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 19, 2025, 7:00 AM EDT - 5 months ago

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 6 months ago

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

Feb 25, 2025, 8:00 AM EST - 6 months ago

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

Feb 24, 2025, 8:00 AM EST - 6 months ago

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

MediWound to launch Phase III trial for venous leg ulcers

Feb 12, 2025, 8:12 AM EST - 6 months ago

MediWound to launch Phase III trial for venous leg ulcers

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

Feb 12, 2025, 7:00 AM EST - 6 months ago

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript

Nov 26, 2024, 1:46 PM EST - 9 months ago

MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 26, 2024, 7:00 AM EST - 9 months ago

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

MediWound Is A Healthy Investment

Oct 29, 2024, 10:49 AM EDT - 10 months ago

MediWound Is A Healthy Investment

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

Oct 10, 2024, 7:00 AM EDT - 11 months ago

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

Aug 15, 2024, 4:15 PM EDT - 1 year ago

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 3:00 PM EDT - 1 year ago

MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 14, 2024, 7:00 AM EDT - 1 year ago

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

Aug 5, 2024, 7:30 AM EDT - 1 year ago

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

MediWound to Report Second Quarter 2024 Financial Results

Aug 2, 2024, 8:00 AM EDT - 1 year ago

MediWound to Report Second Quarter 2024 Financial Results

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

Jul 29, 2024, 8:00 AM EDT - 1 year ago

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

Jul 16, 2024, 7:30 AM EDT - 1 year ago

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

Jul 15, 2024, 7:32 AM EDT - 1 year ago

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

MediWound Announces $25 Million Strategic Private Placement Financing

Jul 15, 2024, 7:00 AM EDT - 1 year ago

MediWound Announces $25 Million Strategic Private Placement Financing

MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript

May 29, 2024, 11:35 AM EDT - 1 year ago

MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

May 29, 2024, 7:00 AM EDT - 1 year ago

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

MediWound to Report First Quarter 2024 Financial Results

May 22, 2024, 8:00 AM EDT - 1 year ago

MediWound to Report First Quarter 2024 Financial Results

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

Apr 25, 2024, 8:00 AM EDT - 1 year ago

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 11:35 AM EDT - 1 year ago

MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Mar 21, 2024, 7:00 AM EDT - 1 year ago

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

Mar 14, 2024, 8:00 AM EDT - 1 year ago

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

Feb 12, 2024, 7:00 AM EST - 1 year ago

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

MediWound to Participate in Two Upcoming Investor Conferences

Feb 5, 2024, 8:00 AM EST - 1 year ago

MediWound to Participate in Two Upcoming Investor Conferences

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

Jan 9, 2024, 7:00 AM EST - 1 year ago

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

Dec 28, 2023, 7:00 AM EST - 1 year ago

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Dec 21, 2023, 8:00 AM EST - 1 year ago

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

MediWound Ltd. (MDWD) Q3 2023 Earnings Call Transcript

Nov 21, 2023, 1:14 PM EST - 1 year ago

MediWound Ltd. (MDWD) Q3 2023 Earnings Call Transcript

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 21, 2023, 7:02 AM EST - 1 year ago

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

Nov 21, 2023, 7:00 AM EST - 1 year ago

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

MediWound to Report Third Quarter 2023 Financial Results

Nov 14, 2023, 8:02 AM EST - 1 year ago

MediWound to Report Third Quarter 2023 Financial Results

MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

Nov 13, 2023, 7:00 AM EST - 1 year ago

MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

Nov 8, 2023, 7:00 AM EST - 1 year ago

MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

MediWound Announces Collaboration with 3M on EscharEx® Phase III Study

Oct 11, 2023, 6:00 AM EDT - 2 years ago

MediWound Announces Collaboration with 3M on EscharEx® Phase III Study

novelty
novelty Aug. 22 at 3:56 PM
$MDWD Bidless warrior
0 · Reply
novelty
novelty Aug. 22 at 1:59 PM
$MDWD bahahaha hah
0 · Reply
novelty
novelty Aug. 22 at 1:41 PM
$MDWD the Bidless warrior
0 · Reply
novelty
novelty Aug. 22 at 1:34 PM
$MDWD lmfao
0 · Reply
novelty
novelty Aug. 21 at 1:59 PM
$MDWD lmfao tank it market maker
0 · Reply
novelty
novelty Aug. 21 at 1:44 PM
$MDWD worst company ever the way this trades someone should be charged with manipulation
0 · Reply
novelty
novelty Aug. 21 at 1:40 PM
$MDWD should be able to scoop 14’s again now that Zee Contrarian is pumping.
0 · Reply
novelty
novelty Aug. 20 at 8:36 PM
$MDWD zee contrarian is a pumper
0 · Reply
JohnPDaly
JohnPDaly Aug. 20 at 6:32 PM
$MDWD https://x.com/zeecontrarian1/status/1958232584170746315?s=12
1 · Reply
novelty
novelty Aug. 20 at 3:30 PM
$MDWD the trading here is so controlled it’s hilarious.
0 · Reply
novelty
novelty Aug. 20 at 1:18 PM
$MDWD hahaha back to 14 we come
0 · Reply
JohnPDaly
JohnPDaly Aug. 20 at 11:38 AM
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference | MediWound $MDWD https://ir.mediwound.com/news-releases/news-release-details/mediwound-present-hc-wainwright-27th-annual-global-investment
0 · Reply
novelty
novelty Aug. 19 at 1:29 PM
$MDWD sooooo bad
0 · Reply
JohnPDaly
JohnPDaly Aug. 19 at 11:13 AM
SEC Filing | MediWound $MDWD insider buys Lads. https://ir.mediwound.com/node/11886/html
0 · Reply
novelty
novelty Aug. 18 at 11:55 PM
$MDWD oooof
0 · Reply
novelty
novelty Aug. 18 at 8:17 PM
$MDWD they puke this volumeless pig soooo easy. We get 14’s again soon
0 · Reply
novelty
novelty Aug. 18 at 7:10 PM
$MDWD easiest thing to tank in the entire market.
0 · Reply
novelty
novelty Aug. 18 at 6:24 PM
$MDWD back to 16’s we go
0 · Reply
Greenpa
Greenpa Aug. 14 at 8:34 PM
$MDWD Solid call. DOD and BARDA really backing company. Steady progress. Nifty move to add more wound care companies to the trials. Hard to see how this doesn’t become standard of care in big markets. Just checking all the boxes. To me, the uncertainty lies only in how quickly and for how much there is a buyout. I’m guessing between $50 to $100 within 3 years. Not bad given little to no downside.
1 · Reply
JohnPDaly
JohnPDaly Aug. 14 at 3:06 PM
$LCTX $MDWD bought more.
1 · Reply
omenkes
omenkes Aug. 14 at 3:02 PM
$MDWD a variable to look at: Clal Biotechnology holds about 1.5M shares. they were supposed to pay down a $5.2M shareholder loan by end of september to Access Industies (who owns 48% of Clal Biotechnology) and now Access decided to prolong the loan until end of 2026 (at interest rate of 5% instead of 2.7% before...), so no sale of 300,000 shares to happen for now. 2026 interim phase 3 results for vlu should be a catalyst and so is the finish of the increased capacity plant.
0 · Reply
enalpa
enalpa Aug. 14 at 1:39 PM
$MDWD what is your estimate on the timeframe before this thing takes off? 2026 or 2027 or beyond?
0 · Reply